TX-MARY-KAY
15.2.2024 18:14:28 CET | Business Wire | Press release
Since 2021, Mary Kay Inc. has partnered with the Equal Rights Trust (ERT), an organization whose mission is to advance equality through law around the world. As part of this collaboration, Mary Kay Inc. supported new research focused on understanding and addressing the discriminatory impacts of artificial intelligence (AI) and its impacts on gender equality, and the development of a new “equality by design approach.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215911706/en/
“Our collaboration with Equal Rights Trust underscores our dedication to ensuring that technological advancements, especially in AI, champion gender equality. The impact of the Principles on Equality by Design in Algorithmic Decision-Making has already been transformative for key stakeholders in AI and echoes our commitment to helping create an inclusive digital economy where women entrepreneurs can excel without bias or barriers,” said Melinda Foster Sellers, Chief People Officer at Mary Kay Inc. (Photo: Mary Kay Inc.)
The initiative culminated with the recent launch of a new set of legal standards – the Principles on Equality by Design in Algorithmic Decision-Making – developed by the Equal Rights Trust and endorsed by a group of leading international equality organizations. The Principles elaborate why national governments and businesses must adopt such an approach and provide detailed guidance for its implementation.
Jim Fitzgerald, Director of Equal Rights Trust, just released an article highlighting the rapid advancements and transformative potential of artificial intelligence while also warning about adverse impacts and discriminatory threats unregulated algorithmic systems could pose.
- Read Jim Fitzgerald’s article titled Equality by Design: A Model for Managing Discriminatory Risks of AI here.
Statements from Jim Fitzgerald, Director of Equal Rights Trust and Melinda Foster Sellers, Chief People Officer at Mary Kay Inc., can be found below:
- “Over the last three years, Mary Kay has supported our research, analysis, and consultation on algorithmic discrimination, and enabled us to develop the Principles on Equality by Design,” said Jim Fitzgerald, Director of the Equal Rights Trust. “Now, Mary Kay is working with us as we move into the next phase: a collaborative effort to develop practical guidance for business on how to adopt the equality by design approach. In doing so, it is taking the next step in a journey which started with strong internal equality and non-discrimination policies, moved to collaboration with and support for us and other actors in this field, and is now focused on incubating and piloting best practice. In this journey, Mary Kay is helping to model how businesses can play an active role in developing improved approaches to eliminating discrimination and advancing equality.”
- "At Mary Kay, we recognize the profound impact that AI has on shaping the future of business and society,” said Melinda Foster Sellers, Chief People Officer at Mary Kay Inc. “Our collaboration with Equal Rights Trust underscores our dedication to ensuring that technological advancements, especially in AI, champion gender equality. The impact of the Principles on Equality by Design in Algorithmic Decision-Making has already been transformative for key stakeholders in AI and echoes our commitment to helping create an inclusive digital economy where women entrepreneurs can excel without bias or barriers. This partnership reflects our enduring mission to empower women and promote equality in every sphere."
About Equal Rights Trust
The Equal Rights Trust is an independent international non-governmental organization which exists to eliminate discrimination and ensure everyone can participate in society on an equal basis. To achieve this, it works in partnership to provide expert support to those on the frontlines of the fight against discrimination, enabling them to press for the development, adoption, and implementation of equality law, and to use the law effectively. Since 2007, the Trust has supported equality activists in more than 50 countries, while developing consensus at the international level on the need for and content of comprehensive equality laws. Learn more at equalrightstrust.org
About Mary Kay
Then. Now. Always. One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 35 countries. For 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com. Find us on Facebook, Instagram, and LinkedIn, or follow us on X (formerly known as Twitter)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215911706/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
